On this basis, limiting the accumulation and spreading of tau aggregates may offer a distinct approach or cooperative approach (e.g., with anti-Aß antibodies) to limit development and progression of AD and other tauopathies. The gene discussed is MAPT; the disease is Alzheimer disease.